CA3113414A1 - Psychedelics protocol computer systems and methods - Google Patents
Psychedelics protocol computer systems and methodsInfo
- Publication number
- CA3113414A1 CA3113414A1 CA3113414A CA3113414A CA3113414A1 CA 3113414 A1 CA3113414 A1 CA 3113414A1 CA 3113414 A CA3113414 A CA 3113414A CA 3113414 A CA3113414 A CA 3113414A CA 3113414 A1 CA3113414 A1 CA 3113414A1
- Authority
- CA
- Canada
- Prior art keywords
- protocol
- client
- psychedelics
- processor
- integration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001337 psychedelic effect Effects 0.000 title claims abstract description 76
- 239000003196 psychodysleptic agent Substances 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 25
- 230000010354 integration Effects 0.000 claims abstract description 61
- 239000003814 drug Substances 0.000 claims description 47
- 230000004044 response Effects 0.000 claims description 18
- 238000004891 communication Methods 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 description 49
- 238000012806 monitoring device Methods 0.000 description 8
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 7
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 description 7
- 230000036651 mood Effects 0.000 description 5
- 238000005352 clarification Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 2
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/20—ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Developmental Disabilities (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Social Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Bioethics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3113414A CA3113414A1 (en) | 2021-03-29 | 2021-03-29 | Psychedelics protocol computer systems and methods |
| PCT/CA2022/050471 WO2022204805A1 (en) | 2021-03-29 | 2022-03-29 | Treatment protocol computer systems and methods |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3113414A CA3113414A1 (en) | 2021-03-29 | 2021-03-29 | Psychedelics protocol computer systems and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3113414A1 true CA3113414A1 (en) | 2022-09-29 |
Family
ID=83439932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3113414A Pending CA3113414A1 (en) | 2021-03-29 | 2021-03-29 | Psychedelics protocol computer systems and methods |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA3113414A1 (enrdf_load_html_response) |
| WO (1) | WO2022204805A1 (enrdf_load_html_response) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240203553A1 (en) * | 2022-12-19 | 2024-06-20 | Andria Orlowski | Opioid treatment system & method |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617351B2 (en) * | 2012-04-23 | 2020-04-14 | Sackett Solutions & Innovations Llc | Cognitive biometric systems to monitor emotions and stress |
| AU2014338867A1 (en) * | 2013-10-25 | 2016-05-19 | Ares Trading S.A. | Patient care system reporting adherence to treatment regimen |
| MX381449B (es) * | 2015-01-10 | 2025-03-12 | Deborah Dullen | Método y aparato para la medición de la función autónoma para el diagnóstico y la validación de tratamientos y resultados de pacientes |
| US11798689B2 (en) * | 2016-07-25 | 2023-10-24 | Viecure, Inc. | Generating customizable personal healthcare treatment plans |
| CA3079560A1 (en) * | 2017-10-19 | 2019-04-25 | Eleusis Benefit Corporation, Pbc | Methods and systems for enhancing safety of psychedelic drug therapies |
| JP7608171B2 (ja) * | 2018-06-19 | 2025-01-06 | エリプシス・ヘルス・インコーポレイテッド | 精神的健康評価のためのシステム及び方法 |
| PT3927337T (pt) * | 2019-02-22 | 2024-05-17 | Gh Res Ireland Limited | 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para o tratamento da depressão major |
| EP3934633A4 (en) * | 2019-03-07 | 2023-03-29 | Arbormentis LLC | COMPOSITIONS AND METHODS OF USE INCLUDING SUBSTANCES HAVING NEURAL PLASTICITY ACTIONS ADMINISTERED IN NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSES AND FORMULATIONS |
| KR102643554B1 (ko) * | 2019-03-22 | 2024-03-04 | 코그노아, 인크. | 개인 맞춤식 디지털 치료 방법 및 디바이스 |
| US10559386B1 (en) * | 2019-04-02 | 2020-02-11 | Kpn Innovations, Llc | Methods and systems for an artificial intelligence support network for vibrant constituional guidance |
| CN114206349A (zh) * | 2019-04-17 | 2022-03-18 | 指南针探路者有限公司 | 治疗神经认知障碍、慢性疼痛及减轻炎症的方法 |
-
2021
- 2021-03-29 CA CA3113414A patent/CA3113414A1/en active Pending
-
2022
- 2022-03-29 WO PCT/CA2022/050471 patent/WO2022204805A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022204805A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10827926B2 (en) | Systems and methods for assessing cognitive function | |
| US10170016B2 (en) | Comprehensive management of human health | |
| Hochman et al. | Loss aversion in the eye and in the heart: The autonomic nervous system's responses to losses | |
| Perry et al. | Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients | |
| Hajcak et al. | Errors are aversive: Defensive motivation and the error-related negativity | |
| Tesser et al. | Self-evaluation maintenance and the mediational role of emotion: The perception of friends and strangers. | |
| JP7487872B2 (ja) | 医療システム及びそれを実行する方法 | |
| Gazarian et al. | A description of nurses' decision‐making in managing electrocardiographic monitor alarms | |
| Loring et al. | A brief behavioral intervention for insomnia in adolescents with autism spectrum disorders | |
| Zdanowicz et al. | Insomnia, sleepiness, and fatigue among polish nurses | |
| Carter et al. | Autonomous and controlled motivation for eating disorders treatment: baseline predictors and relationship to treatment outcome | |
| Brunet et al. | Validation of sleep-2-Peak: A smartphone application that can detect fatigue-related changes in reaction times during sleep deprivation | |
| Cao et al. | Differences in day and night shift clinical performance in anesthesiology | |
| Riley | Patient fatigue during aphasia treatment: A survey of speech-language pathologists | |
| JP7391443B1 (ja) | 医療・療法システムを統合するデータベース及びそれを実行する方法 | |
| Tremaine et al. | Actigraph estimates of the sleep of Australian midwives: the impact of shift work | |
| JP2023155465A (ja) | 医療・療法システムを統合するデータベース及びそれを実行する方法 | |
| Valeriani et al. | Correlation between abnormal brain excitability and emotional symptomatology in paediatric migraine | |
| CA3113414A1 (en) | Psychedelics protocol computer systems and methods | |
| Fowers et al. | Using mobile meditation app data to predict future app engagement: an observational study | |
| Greenlee et al. | Modality changes in vigilance displays: further evidence of supramodal resource depletion in vigilance | |
| Charles et al. | Feeling free: External influences on endogenous behaviour | |
| Massar et al. | Sleep, well-being, and cognition in medical interns on a float or overnight call schedule | |
| Bault et al. | Dissociation between private and social counterfactual value signals following ventromedial prefrontal cortex damage | |
| Klauß et al. | Learning by observing: a systematic exploration of modulatory factors and the impact of observationally induced placebo and nocebo effects on treatment outcomes |